GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Forward PE Ratio

Median Technologies (XPAR:ALMDT) Forward PE Ratio : 0.00 (As of Jun. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Median Technologies Forward PE Ratio?

Median Technologies's Forward PE Ratio for today is 0.00.

Median Technologies's PE Ratio without NRI for today is 0.00.

Median Technologies's PE Ratio for today is 0.00.


Median Technologies Forward PE Ratio Historical Data

The historical data trend for Median Technologies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Technologies Forward PE Ratio Chart

Median Technologies Annual Data
Trend
Forward PE Ratio

Median Technologies Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Median Technologies's Forward PE Ratio

For the Medical Devices subindustry, Median Technologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Median Technologies's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Median Technologies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Median Technologies's Forward PE Ratio falls into.



Median Technologies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Median Technologies  (XPAR:ALMDT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Median Technologies Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Median Technologies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Median Technologies (XPAR:ALMDT) Business Description

Traded in Other Exchanges
Address
1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies (XPAR:ALMDT) Headlines

No Headlines